Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR-positive, HER2-negative Breast Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchEnded earlyNCT03361800
What this trial is testing

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

Who this might be right for
Breast CancerInvasive Breast CancerER-Negative PR-Negative HER2-Negative Breast Cancer
UNC Lineberger Comprehensive Cancer Center 5
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07745257
What this trial is testing

Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases

Who this might be right for
HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases
Sun Yat-sen University 40
Early research (Phase 1)Not Yet RecruitingNCT07163481
What this trial is testing

A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

Who this might be right for
Stage IV (Metastatic) Breast Cancer
Hunan Cancer Hospital 12
Early research (Phase 1)Looking for participantsNCT07029399
What this trial is testing

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
HR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid Tumors+1 more
NiKang Therapeutics, Inc. 361
Testing effectiveness (Phase 2)Active Not RecruitingNCT06001762
What this trial is testing

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Who this might be right for
Breast CancerEarly-stage Breast CancerHigh Risk Breast Carcinoma
Dana-Farber Cancer Institute 90
Early research (Phase 1)Looking for participantsNCT05683418
What this trial is testing

Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Who this might be right for
HR+/HER2-negative Breast Cancer
Totus Medicines 241
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05979220
What this trial is testing

Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy

Who this might be right for
Breast Cancer
Shuangyue Liu 178
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07730125
What this trial is testing

Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies

Who this might be right for
HR-positive, HER2-negative Breast CancerTNBC - Triple-Negative Breast CancerProstate Cancer
CoRegen, Inc. 67
Not applicableStudy completedNCT02023359
What this trial is testing

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Healthcare A/S 7
Early research (Phase 1)Looking for participantsNCT06756932
What this trial is testing

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Who this might be right for
Hormone-receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
BeOne Medicines 120
Large-scale testing (Phase 3)Looking for participantsNCT06757634
What this trial is testing

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Who this might be right for
Breast Cancer
Celcuity Inc 1,180
Testing effectiveness (Phase 2)Looking for participantsNCT07330544
What this trial is testing

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 118
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07340619
What this trial is testing

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

Who this might be right for
Metastatic (Stage IV) Melanoma
UNICANCER 51
Testing effectiveness (Phase 2)Ended earlyNCT03858972
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 152
Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Large-scale testing (Phase 3)Active Not RecruitingNCT05780567
What this trial is testing

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 1,946
Testing effectiveness (Phase 2)Active Not RecruitingNCT04524000
What this trial is testing

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 24
Not applicableStudy completedNCT01899079
What this trial is testing

A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 217
Not applicableStudy completedNCT05173103
What this trial is testing

Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
University of Milano Bicocca 254
Testing effectiveness (Phase 2)Study completedNCT02871791
What this trial is testing

Palbociclib With Everolimus + Exemestane In BC

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor (HR)-Positive Breast Cancer
Dana-Farber Cancer Institute 41
Next Page